Esther Nkrumah, Ph.D. is VP, Clinical Operations for OrphAI Therapeutics. Dr. Nkrumah has more than 15 years of experience spanning large pharma, biotech, CRO, and academia where she has held numerous roles of increasing responsibility. Prior to joining AI Therapeutics, she led the strategic development of the clinical project management/clinical operations function within GW Pharmaceuticals, enabling effective oversight and support to the complete project lifecycle from clinical trial design to commercialization. Dr. Nkrumah served as the clinical operations lead on the pivotal phase 3 studies which resulted in US and EU market approval of EPIDIOLEX. She has developed and implemented risk management strategies and frameworks for clinical trials, and continuous process improvement activities resulting in effective clinical trials management and oversight. She is an Adjunct Professor of Clinical Research Organization and Management at Drexel University. She also holds a PhD in Health Science from Nova Southeastern University and a Masters in Clinical Research from Drexel University.
